Literature DB >> 2417474

The Cardiac Arrhythmia Pilot Study. The CAPS investigators.

.   

Abstract

Frequent or repetitive ventricular premature complexes (VPCs) occurring soon after acute myocardial infarction are predictors of subsequent mortality independent of left ventricular dysfunction. The Cardiac Arrhythmia Pilot Study (CAPS) is a 10-center study sponsored by the National Heart, Lung, and Blood Institute to determine whether postinfarction ventricular arrhythmias can be satisfactorily reduced for 1 year after acute myocardial infarction. Patients younger than 75 years are screened for arrhythmias 6 to 60 days after acute myocardial infarction. To qualify for CAPS, patients must have at least 10 VPCs or at least 5 runs of 3 to 9 consecutive VPCs in a 24-hour electrocardiographic recording and a left ventricular ejection fraction greater than 0.20. Eligible patients without exclusion criteria are randomized into 1 of 5 treatment tracks (4 active treatment and 1 placebo). Within a treatment track, patients are permitted to change drug and dosage in order to achieve at least 70% reduction in VPC frequency and at least 90% reduction in runs of VPCs over 1 year of follow-up. In addition to efficacy assessment, adverse effects, particularly proarrhythmic effects, are being monitored. The results in CAPS will be pivotal for deciding whether a fullscale trial to determine whether controlling ventricular arrhythmias will reduce mortality risk is feasible.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2417474     DOI: 10.1016/0002-9149(86)90958-6

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  13 in total

1.  Pharmacodynamic effect of continuous vs intermittent dosing of dofetilide on QT interval.

Authors:  Michael J Allen; Stuart D Oliver; Margaret W Newgreen; Donald J Nichols
Journal:  Br J Clin Pharmacol       Date:  2002-01       Impact factor: 4.335

Review 2.  Benefit-risk assessment of nesiritide in the treatment of acute decompensated heart failure.

Authors:  Clyde W Yancy
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

Review 3.  Neuronal sodium channels: emerging components of the nano-machinery of cardiac calcium cycling.

Authors:  Rengasayee Veeraraghavan; Sándor Györke; Przemysław B Radwański
Journal:  J Physiol       Date:  2017-03-26       Impact factor: 5.182

Review 4.  Therapeutic drug monitoring of antiarrhythmic drugs. Rationale and current status.

Authors:  R Latini; A P Maggioni; A Cavalli
Journal:  Clin Pharmacokinet       Date:  1990-02       Impact factor: 6.447

Review 5.  Controlling cardiac arrhythmias: to delay conduction or to prolong refractoriness.

Authors:  B N Singh
Journal:  Cardiovasc Drugs Ther       Date:  1989-10       Impact factor: 3.727

Review 6.  Assessment of the risk-benefit ratio for antiarrhythmic drug use.

Authors:  R W Campbell
Journal:  Drugs       Date:  1988-11       Impact factor: 9.546

7.  Neuronal Na+ channel blockade suppresses arrhythmogenic diastolic Ca2+ release.

Authors:  Przemysław B Radwański; Lucia Brunello; Rengasayee Veeraraghavan; Hsiang-Ting Ho; Qing Lou; Michael A Makara; Andriy E Belevych; Mircea Anghelescu; Silvia G Priori; Pompeo Volpe; Thomas J Hund; Paul M L Janssen; Peter J Mohler; John H B Bridge; Steven Poelzing; Sándor Györke
Journal:  Cardiovasc Res       Date:  2014-12-23       Impact factor: 10.787

8.  Clinical aspects of trial design: what can we expect from the cardiac arrhythmia suppression trial?

Authors:  J T Bigger
Journal:  Cardiovasc Drugs Ther       Date:  1990-06       Impact factor: 3.727

Review 9.  Encainide--an updated safety profile.

Authors:  J A Thomis
Journal:  Cardiovasc Drugs Ther       Date:  1990-06       Impact factor: 3.727

10.  Baroreflex sensitivity and its association with arrhythmic events in Chagas disease.

Authors:  Astrid Meireles Santos; Mauricio Ibrahim Scanavacca; Francisco Darrieux; Bárbara Ianni; Sissy Lara de Melo; Cristiano Pisani; Francisco Santos Neto; Eduardo Sosa; Denise Tessariol Hachul
Journal:  Arq Bras Cardiol       Date:  2014-05-27       Impact factor: 2.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.